KEGG   DRUG: Ombitasvir, paritaprevir and ritonavir
Entry
D10745            Mixture   Drug                                   

Name
Ombitasvir, paritaprevir and ritonavir;
Technivie (TN)
Component
(Ombitasvir hydrate [DR:D10598] | Ombitasvir [DR:D10576]), (Paritaprevir hydrate [DR:D10597] | Paritaprevir [DR:D10580]), Ritonavir [DR:D00427]
Remark
ATC code: J05AP53
Efficacy
Antiviral
  Disease
Chronic hepatitis C virus infection [DS:H00413]
Comment
Paritaprevir is an inhibitor and a substrate of P-gp, BCRP and OATP1B1/1B3.
Ombitasvir is metabolized by P-gp.
Ritonavir is an inhibitor and a substrate of P-gp; it is also an inhibitor of CYP3A4 and BCRP.
Metabolism
Enzyme: CYP3A4 [HSA:1576], CYP3A5 [HSA:1577]
Transporter: ABCB1 [HSA:5243], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234], ABCG2 [HSA:9429]
Interaction
CYP inhibition: CYP3A4 [HSA:1576]
Transporter inhibition: ABCB1 [HSA:5243], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234], ABCG2 [HSA:9429]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AP Antivirals for treatment of HCV infections
     J05AP53 Ombitasvir, paritaprevir and ritonavir
      D10745  Ombitasvir, paritaprevir and ritonavir
USP drug classification [BR:br08302]
 Antivirals
  Anti-hepatitis C (HCV) Agents
   Ombitasvir/ Paritaprevir/ Ritonavir
    D10745  Ombitasvir, paritaprevir and ritonavir
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10745
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10745
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10745
 Drug transporters
  D10745
Other DBs
PubChem: 254741706
ChEBI: 90919
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system